1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
hollywood1450@yahoo.ca
insider
Articles 

Opaleye Management Inc. Buys Protara Therapeutics Inc, Eton Pharmaceuticals Inc, Kala Pharmaceuticals Inc, Sells Epizyme Inc, Turning Point Therapeutics Inc, Audentes Therapeutics Inc

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Protara Therapeutics Inc, Eton Pharmaceuticals Inc, Kala Pharmaceuticals Inc, Molecular Templates Inc, Myovant Sciences, sells Epizyme Inc, Turning Point Therapeutics Inc, Audentes Therapeutics Inc, Intra-Cellular Therapies Inc, Axogen Inc during the 3-months ended 2020Q1, according to the most recent filings of the investment company, Opaleye Management Inc.. As of 2020Q1, Opaleye Management Inc. owns 41 stocks with a total value of $369 million. These are the details of the buys and sells.

For the details of Opaleye Management Inc.'s stock buys and sells, go to https://www.gurufocus.com/guru/opaleye+management+inc./current-portfolio/portfolio

These are the top 5 holdings of Opaleye Management Inc.
  1. Protara Therapeutics Inc (TARA) - 2,208,472 shares, 14.11% of the total portfolio. New Position
  2. Forty Seven Inc (FTSV) - 385,500 shares, 9.96% of the total portfolio. Shares reduced by 31.41%
  3. Ocular Therapeutix Inc (OCUL) - 5,122,500 shares, 6.86% of the total portfolio. Shares added by 0.29%
  4. Aptose Biosciences Inc (APTO) - 4,022,000 shares, 6.47% of the total portfolio. Shares reduced by 1.54%
  5. Neoleukin Therapeutics Inc (NLTX) - 1,400,000 shares, 4.31% of the total portfolio. Shares added by 1.35%
New Purchase: Protara Therapeutics Inc (TARA)

Opaleye Management Inc. initiated holding in Protara Therapeutics Inc. The purchase prices were between $21.02 and $39, with an estimated average price of $29.85. The stock is now traded at around $41.19. The impact to a portfolio due to this purchase was 14.11%. The holding were 2,208,472 shares as of .

New Purchase: Eton Pharmaceuticals Inc (ETON)

Opaleye Management Inc. initiated holding in Eton Pharmaceuticals Inc. The purchase prices were between $2.87 and $7.47, with an estimated average price of $5.9. The stock is now traded at around $4.78. The impact to a portfolio due to this purchase was 4.04%. The holding were 3,640,000 shares as of .

New Purchase: Kala Pharmaceuticals Inc (KALA)

Opaleye Management Inc. initiated holding in Kala Pharmaceuticals Inc. The purchase prices were between $3.69 and $8.79, with an estimated average price of $6.36. The stock is now traded at around $13.09. The impact to a portfolio due to this purchase was 1.96%. The holding were 782,000 shares as of .

New Purchase: Molecular Templates Inc (MTEM)

Opaleye Management Inc. initiated holding in Molecular Templates Inc. The purchase prices were between $11.31 and $18.26, with an estimated average price of $14.57. The stock is now traded at around $16.10. The impact to a portfolio due to this purchase was 1.92%. The holding were 533,400 shares as of .

New Purchase: Myovant Sciences Ltd (MYOV)

Opaleye Management Inc. initiated holding in Myovant Sciences Ltd. The purchase prices were between $6.55 and $15.52, with an estimated average price of $11.33. The stock is now traded at around $12.74. The impact to a portfolio due to this purchase was 1.34%. The holding were 656,000 shares as of .

New Purchase: Catalyst Pharmaceuticals Inc (CPRX)

Opaleye Management Inc. initiated holding in Catalyst Pharmaceuticals Inc. The purchase prices were between $2.61 and $5.21, with an estimated average price of $4.11. The stock is now traded at around $4.42. The impact to a portfolio due to this purchase was 1.09%. The holding were 1,050,000 shares as of .

Added: Crinetics Pharmaceuticals Inc (CRNX)

Opaleye Management Inc. added to a holding in Crinetics Pharmaceuticals Inc by 38.58%. The purchase prices were between $11.52 and $26.46, with an estimated average price of $20.65. The stock is now traded at around $18.36. The impact to a portfolio due to this purchase was 0.41%. The holding were 368,750 shares as of .

Added: Macrogenics Inc (MGNX)

Opaleye Management Inc. added to a holding in Macrogenics Inc by 110.62%. The purchase prices were between $4.28 and $12.11, with an estimated average price of $9.16. The stock is now traded at around $25.37. The impact to a portfolio due to this purchase was 0.35%. The holding were 422,300 shares as of .

Added: Edap TMS SA (EDAP)

Opaleye Management Inc. added to a holding in Edap TMS SA by 22.89%. The purchase prices were between $1.72 and $4.47, with an estimated average price of $3.55. The stock is now traded at around $2.45. The impact to a portfolio due to this purchase was 0.25%. The holding were 2,193,500 shares as of .

Added: Kadmon Holdings Inc (KDMN)

Opaleye Management Inc. added to a holding in Kadmon Holdings Inc by 22.53%. The purchase prices were between $2.44 and $5.16, with an estimated average price of $4.32. The stock is now traded at around $4.66. The impact to a portfolio due to this purchase was 0.24%. The holding were 1,152,250 shares as of .

Sold Out: Epizyme Inc (EPZM)

Opaleye Management Inc. sold out a holding in Epizyme Inc. The sale prices were between $14.83 and $26.72, with an estimated average price of $21.65.

Sold Out: Turning Point Therapeutics Inc (TPTX)

Opaleye Management Inc. sold out a holding in Turning Point Therapeutics Inc. The sale prices were between $32.02 and $66.17, with an estimated average price of $53.48.

Sold Out: Audentes Therapeutics Inc (BOLD)

Opaleye Management Inc. sold out a holding in Audentes Therapeutics Inc. The sale prices were between $59.83 and $60, with an estimated average price of $59.94.

Sold Out: Intra-Cellular Therapies Inc (ITCI)

Opaleye Management Inc. sold out a holding in Intra-Cellular Therapies Inc. The sale prices were between $12.31 and $34.31, with an estimated average price of $22.

Sold Out: Axogen Inc (AXGN)

Opaleye Management Inc. sold out a holding in Axogen Inc. The sale prices were between $8.38 and $17.89, with an estimated average price of $12.85.

Sold Out: PTC Therapeutics Inc (PTCT)

Opaleye Management Inc. sold out a holding in PTC Therapeutics Inc. The sale prices were between $32.37 and $59.36, with an estimated average price of $50.48.

Reduced: ACADIA Pharmaceuticals Inc (ACAD)

Opaleye Management Inc. reduced to a holding in ACADIA Pharmaceuticals Inc by 99.27%. The sale prices were between $31.65 and $46.87, with an estimated average price of $41.34. The stock is now traded at around $51.24. The impact to a portfolio due to this sale was -1.8%. Opaleye Management Inc. still held 1,500 shares as of .

Reduced: Forty Seven Inc (FTSV)

Opaleye Management Inc. reduced to a holding in Forty Seven Inc by 31.41%. The sale prices were between $35.28 and $95.42, with an estimated average price of $59.7. The stock is now traded at around $95.51. The impact to a portfolio due to this sale was -1.43%. Opaleye Management Inc. still held 385,500 shares as of .

Reduced: Amarin Corp PLC (AMRN)

Opaleye Management Inc. reduced to a holding in Amarin Corp PLC by 31.58%. The sale prices were between $4 and $21.53, with an estimated average price of $16.75. The stock is now traded at around $7.24. The impact to a portfolio due to this sale was -0.93%. Opaleye Management Inc. still held 455,000 shares as of .

Reduced: Flexion Therapeutics Inc (FLXN)

Opaleye Management Inc. reduced to a holding in Flexion Therapeutics Inc by 32.23%. The sale prices were between $5.53 and $21.13, with an estimated average price of $15.21. The stock is now traded at around $9.77. The impact to a portfolio due to this sale was -0.57%. Opaleye Management Inc. still held 281,600 shares as of .

Reduced: Zymeworks Inc (ZYME)

Opaleye Management Inc. reduced to a holding in Zymeworks Inc by 24%. The sale prices were between $24.28 and $49.8, with an estimated average price of $41.23. The stock is now traded at around $36.16. The impact to a portfolio due to this sale was -0.39%. Opaleye Management Inc. still held 133,000 shares as of .



Here is the complete portfolio of Opaleye Management Inc.. Also check out:

1. Opaleye Management Inc.'s Undervalued Stocks
2. Opaleye Management Inc.'s Top Growth Companies, and
3. Opaleye Management Inc.'s High Yield stocks
4. Stocks that Opaleye Management Inc. keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)